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Abstract
Background: Increased plasma Urotensin II (UII) levels have been found in adults with renal diseases. Studies in
children are scarce. The objective of the study is to estimate plasma UII levels in subjects with chronic kidney
disease (CKD) stages 3 to 5 and renal transplant recipients (RTR). In addition, the correlation of UII with
anthropometric features and biochemical parameters was assessed.
Methods: Fifty-four subjects, aged 3 to 20 years old, 23 with CKD, 13 with end-stage kidney disease (ESKD)
undergoing hemodialysis (HD) and 18 RTR were enrolled. A detailed clinical evaluation was performed. Biochemical
parameters of renal and liver function were measured. Plasma UII levels were measured in all patients and in 117
healthy controls, using a high sensitive enzyme immunoassay (EIA) kit. All data were analyzed using STATA™
(Version 10.1).
Results: Median UII and mean log-transformed UII levels were significantly higher in CKD and RTR patients
compared to healthy subjects (p < 0.001). HD patients had higher but not statistically significant UII and log-UII
levels than controls. UII levels increased significantly at the end of the HD session and were higher than controls
and in line to those of other patients. The geometric scores of UII in HD (before dialysis), CKD and RTR patients
increased respectively by 42, 136 and 164% in comparison with controls. Metabolic acidosis was associated with
statistical significant change in log-UII levels (p = 0.001). Patients with metabolic acidosis had an increase in UII
concentration by 76% compared to those without acidosis.
Conclusions: Children and adolescents with CKD, particularly those who are not on HD and RTR, have significantly
higher levels of UII than healthy subjects. UII levels increase significantly at the end of the HD session. The presence
of metabolic acidosis affects significantly plasma UII levels.
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Background
Urotensin II (UII) is the most potent vasoconstrictor
peptide in humans. It has also been reported to have a
vasodilatory effect on small arteries of rats as well as on
resistance arteries of humans [1–3]. It is synthesized
mainly in the kidney, but also in non-renal tissues such
as the heart, liver, pancreas and adrenal glands [4]. The
high levels of plasma UII in surgically anephric patients
is a strong indication of extrarenal production [5].
Increased plasma UII levels have been found in many
pathological conditions such as hypertension, cirrhosis,
congestive heart failure and renal failure, but the role of
UII in human diseases, including renal disease, is still
controversial [6–14]. Initial evidence suggested that UII
contributes to the development of cardiovascular diseases
as well as renal dysfunction, however in the last decade
many studies have shown a possible cardioprotective
role of high UII levels in patients with ischemic heart
disease and chronic kidney disease (CKD) [11, 15, 16].
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Furthermore, low UII levels have been associated
with cardiovascular events and death in adults with
CKD [17, 18].
There is limited information on UII levels in children.
There are few reports on UII levels in children and
adolescents with pulmonary hypertension, portal hyper-
tension, congenital heart disease and nephrotic syn-
drome [19–23].
To our knowledge this is the first study of plasma UII
levels in children and adolescents with CKD of stages
3–5, ESKD on dialysis and renal transplantation.
The aim of the present study was to evaluate prospect-
ively plasma UII concentration in the above pediatric
population; its association with management options
(dialysis or no dialysis, renal transplantation) and its




In this single - centre prospective study, fifty-four
Caucasian children and adolescents (33 boys, 21 girls),
aged 3 to 20 years old, twenty-three with CKD stages 3–5,
thirteen with ESKD who were on regular dialysis treat-
ment and eighteen RTR, were enrolled. The mean age had
no statistically significant difference between the three
groups (p 0.424). The underlying causes of chronic
kidney disease include: Hypodysplasia ± reflux nephropa-
thy (n = 23), obstructive uropathy (n = 6), glomeruloneph-
ritis (n = 6), congenital kidney and urinary tract anomalies
(CAKUT, n = 5), cystic kidney disease (n = 3), congenital
nephrotic syndrome (n = 3), hereditary nephropathy
(n = 3), hemolytic uremic syndrome (HUS, n = 2), mis-
cellaneous(n = 1), unknown (n = 2). One hundred and
seventeen age-matched (p = 0.242) healthy children
and adolescents comprised the control group. Patients
and controls were recruited from the Department of
Nephrology and from the 2nd Department of Pediatrics of
Athens University of the “P. & A. Kyriakou” Children’s’
Hospital respectively. The study was conducted from May
2012 to February 2014 and was approved by the Hospital’s
Ethics Committee prior to its initiation. All participants’
parents or legal guardians were required to complete a
consent form. Parents of only one child with CKD refused
to participate in the study. The following exclusive criteria
were mandatory for the patients group: children below
3 years of age, CKD stages 1 and 2, duration of dialysis
and transplantation less than 2 and 6 months respectively
and those with co-occurrence of hepatic, pulmonary or
congenital heart disease.
Definition and classification of CKD
For the definition of CKD we used the criteria recom-
mended by Kidney Disease Quality Outcome Initiative
(K/DOQI) [24]. CKD staging was based on the estimated
Glomerular Filtration Rate (eGFR) according to the
KDOQI CKD classification. The eGFR was calculated in
ml/min/1.73 m2 according to Schwartz formula [25].
Graft function was also classified to CKD 1–5 stages.
Anthropometric features, clinical evaluation and medical
data
In all participants, anthropometric features, personal and
family history were evaluated; and a detailed physical
examination was carried out. The body weight (BW) was
measured to the nearest 0.1 kg using an electronic scale
(SECA) and the height (Ht) to the nearest 0.1 cm by a wall
stadiometer (Hyssna). BSA was calculated in m2.
The “dry weight” was also estimated in patients
undergoing dialysis with the use of a body composition
monitor. Body mass index (BMI) was calculated by the
equation: BW (kg) per Ht (m2). Participants were classi-
fied as normal BMI, overweight (OW) and obese (OB)
using the International growth charts [26]. Moreover,
standard deviation scores (SDS) for BW, Ht and BMI
were calculated using a standardized age- and sex- spe-
cific calculator. Blood pressure (BP) was measured by an
electronic automated oscillometric device Dynamap with
a suitable cuff size (Critikon) for the child’s arm circum-
ference. Three BP measurements (with one minute
interval) were taken in a sitting position after a 5 min
rest. The average of these measurements was used in the
analysis. The systolic BP (SBP) and diastolic BP (DBP)
values were classified using chart percentiles for age, sex
and height and hypertension was defined as BP equal or
above the 95th percentile [27]. SDS for SBP and DBP were
also calculated by a standardized calculator based on age,
sex and height. A full cardiological evaluation was per-
formed in all patients. Left ventricular mass (LVM) and
left ventricular mass index (LVMI) were estimated.
Twelve out of 13 patients underwent conventional
hemodialysis three times a week and one patient four
times a week, approximately 4.5 h per session. The dialy-
sis machines that were used were Gambro AK200S and
Nikisso model dbb 05. Dialysers were chosen according to
body surface area (BSA). In these subjects, BW, BMI and
BP were re-evaluated after the completion of dialysis.
The mean duration of hemodialysis (HD) was 1.2 (SD
0.9) years. The mean duration of transplantation was 5.6
(SD 2.2) years. All RTR patients were on immunosup-
pressive drug treatment with prednisolone, mycopheno-
late and cyclosporine or tacrolimus.
Laboratory tests
Venous blood samples were collected between 8–9 am,
after an overnight fast in all participants. All children
were infection free for at least 10 days before the
examination.
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Biochemical parameters such as urea, creatinine, total
protein, albumin, uric acid, electrolytes, transaminases and
γGT were measured in serum using standard laboratory
methods. Cystatin C was measured using an automated
particle-enhanced nephelometric immunoassay (PENIA)
on a Siemens Behring Nephelometer BN II system. Venous
blood gases and a full blood count were obtained.
We defined anemia as levels of hemoglobin below the
lowest limit of normal for age and sex. Metabolic acid-
osis was defined as pH <7.35 and base < 22 mmol/L.
For the determination of UII, whole venous blood in
EDTA tubes was collected; it was immediately placed in
ice and then centrifuged at 1600 g for 10 min at 4 °C.
The supernatant was stored in aliquots of 200 μl at -70 °C
until the time of analysis. Plasma UII levels were measured
by a high sensitive enzyme immunoassay (EIA) kit
(Phoenix Pharmaceuticals, Inc. 330 Beach Road,
Burlinghame, CA 94010, USA) and expressed in ng/ml.
The intra-assay and the inter-assay variation CV% were
<5% and <14% respectively. The range was 0–100 ng/
ml, the linear range 0.06–1.48 ng/ml, and the detection
limit 0.06 ng/ml.
In patients undergoing hemodialysis the markers of
renal function and plasma UII concentration were evalu-
ated twice, before the initiation and after the completion
of midweek dialysis session.
Statistical analysis
The Shapiro-Wilk test was performed to test for normal
distribution of continuous variables. The results are given
as mean (+/- SD) or as median and interquartile range
(IQR) according to normality of relative frequencies. All
qualitative variables are presented as absolute or relative
frequencies.
The Student’s t-test or its non-parametric equivalent
Mann-Whitney U test was used to compare continuous
variables between the groups under study. The Fisher’s
exact test was employed for comparison of categorical var-
iables. One way analysis of variance (ANOVA) or Kruskal
Wallis test was used for comparison of parametric and
non-parametric variables between groups, respectively.
Sidak correction was used for multiple comparisons.
Urotensin II levels had to be log-transformed in order
to achieve a normal distribution in patients (Fig. 1) and
healthy controls (data not shown).
Log transformed UII values were used as the dependent
variable for the linear regression analysis and in multiple
regression models in order to investigate the relationship
between UII and a series of factors. Since log-transformed
UII was used all interpretations are presented as propor-
tion change in geometric mean of UII values.
Study groups and each one of the variables such as age,
disease duration, markers of renal function (e.g. eGFR,
creatinine, cystatin C and electrolytes) and hemodynamic
parameters (SBP, DBP, heart rate, LVM and LVMI), were
used as independent variables. The non parametric
Spearman correlation coefficient was applied in order to
associate UII levels with several factors.
All tests were two-tailed and statistical significance
was established at p = 5%. Data were analyzed using
STATA™ (Version 10.1 MP, Stata Corporation, College
Station, TX, 77845, USA).
Results
The anthropometric features and clinical characteristics
of the three groups of patients are shown in Table 1.
Children undergoing HD had greater growth retardation
and greater percentage of hypertension compared to
other groups (Table 1). Moreover, Systolic and Diastolic
BP as well as SDS of SBP and DBP were lower but the dif-
ferences had no statistical significance (p = 0.119, p = 0.148,
p = 0.145 and p = 0.131 respectively). A significant decrease
in body weight (1.19 ± 0.85 kg) after the completion of HD
was established (p = 0.001).
Laboratory data for three study groups are shown in
Table 2. Children on HD had significantly lower mean
hemoglobin and hematocrit than CKD group. Moreover,
anemia was more common in HD group, compared to
other groups. In addition, serum chloride was lower in
HD than other groups and serum potassium was signifi-
cantly higher only compared to RTR group. Finally,
serum albumin concentration was lower in HD children
compared to CKD patients (Table 2).
Median UII and mean log-transformed UII levels were
significantly higher in CKD and RTR patients compared
to healthy controls (p < 0.001 and p < 0.001). HD patients
had also higher UII and log-UII levels than controls but
there was not statistical significance (Fig. 2, Table 3).
The increase of the mean of UII scores, by switching
from controls to HD, CKD and RTR patients, was 42,
136 and 164% respectively. There was also an increase in
the mean of UII scores of 86% by switching from HD to
RTR patients (p < 0.05).
Finally, in HD patients UII and log-transformed UII
were increased significantly after the completion of dia-
lysis [2.42 (1.6–2.79) vs 4.38 (2.17–7.62), p = 0.043 and
0.71 (SD 0.53) vs 1.45 (SD 0.96), p = 0.022 respectively)
and there was no significant difference compared to
other patient groups. Moreover, an increase of approxi-
mately 197% in the mean of U II scores is observed
(p < 0.05) when switching from controls to HD pa-
tients measured at the end of their dialysis session.
There was no correlation found between BW, Dry
BW and their SDS with UII levels before and after
the completion of dialysis. Furthermore, the increase
of UII did not correlate with the decrease of body
weight (p = 0.640), the improvement of renal function
and the decrease of blood pressure.
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Gender (Males %) 74 54 50 0.284
Age (years) 11.5 (4.8) 10.3 (3.6) 12.3 (3.8) 0.424
eGFR (ml/min/1.73 m2) 31.0 [22, 47]a 6.0 [6, 7]b 58.5 [47, 63]c <0.001
Disease duration (yrs) 8.9 (4.8) 7.6 (4.4) 9.8(3.2) 0.391
SDS-Weight -0.44 [-1.23, 0.62]a -1.84 [-3.41, -0.86]b 0.41 [-0.37, 0.75]a 0.001
SDS-Height -0.90 (1.01)a -2.92 (1.60)bc -1.98 (0.94)c <0.001
BSA (m2) 1.24 (0.42)a 0.90 (0.23)b 1.27 (0.32)ac 0.012
BMI (kg/m2) 18.8 [16.9, 21.9]ab 15.9 [14.9, 18.4]a 21.7 [18.4, 26.7]b 0.004
SDS-BMI 0.41 [0.02, 1.2]ab -0.70 [-1.29, 0.53]a 1.26 [0.61, 1.79]b 0.006
BMI (Increased %) 26.1 26.1 72.2 0.004
Fat (%) 19.7 [14.7, 23.9] 13.7 [12.6, 19.3] 20.2 [15.6, 24.5] 0.125
Lean Body Mass (kg) 34.2 [20.3, 41.8]a 19 [17.7, 24.2]b 35.8 [25.9, 43.9]a 0.004
SDS-dry Weight -2.55 [1.97]
BMI-dry weight (kg/m2) 14.9 [14.5,18.1]
SDS-BMI (dry weight) -0.85 [1.7]
Systolic BP (mmHg) 103.5 (16.4) 111.9 (21.0) 113.6 (12.9) 0.128
SDS -Systolic BP -0.002 (1.30)a 1.36 (2.08)b 1.14 (0.98)b 0.011
Diastolic BP (mmHg) 60.2 (11.7)a 70.9 (16.9)ab 71.1 (8.6)b 0.009
SDS- Diastolic BP -0.02 (1.13)a 1.06 (1.32)b 0.96 (0.73)b 0.004
Increased BP (%) 17.4 61.5 16.7 0.012
CKD chronic Kidney Disease, HD Hemodialysis, RTR Renal Transplant Recipients, eGFR estimated Glomerular Filtration Rate, BSA Body Surface Area, BMI Body Mass
Index, SDS Standard Deviation Scores, BP Blood Pressure, Increased BP: above the 95th percentile for gender, age and height. Superscript letters a, b, c
denote values of different statistical significance
*Results are presented as mean (SD) or as median [IQR] according to data distribution. Tests employed are one way ANOVA and Kruskal – Wallis test, respectively.
For qualitative data Fisher’s exact test was applied. Tests employed are paired t test or Mann–Whitney U test, respectively
Fig. 1 Distribution of plasma Urotensin II levels and log-transformed UII levels in patients
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There was no statistically significant difference in log-
UII levels according to sex, age and body mass index in
patients and controls.
UII levels in patients were negatively correlated
with serum creatinine (r -0.37, p = 0.006) and cystatin
C (r -0.44, p = 0.001). In addition, Spearman’s correl-
ation coefficient was applied for the same pairs of
factors per group. No statistical significant association
was detected between any pair of factors (p > 0.05).
For this reason, CKD and HD were merged, resulting
in a significant negative correlation of UII with
creatinine (r -0.46, p = 0.004) and cystatin C (r -0.41,
p = 0.001) and a positive one with serum albumin
levels (r 0.36, p = 0.032).
Linear regression analysis revealed that metabolic
acidosis was associated with a statistical significant
change in log-transformed UII levels (p = 0.010). More
specifically, by switching from non-acidosis to acidosis
a 76% increase in the mean of UII scores is observed.
For a 0.1 units increase of pH and for a 1 mEq/L in-
crease of HCO3, a decrease of approximately 50 and
7% respectively in the mean of UT II scores is ex-
pected (Table 4).
Linear regression analysis of log UT II adjusted for
LVM by group indicated that when switching from
CDK to HD, a 55% decrease in the mean of UII
scores is to be expected (Table 5). Finally, UII levels
were positively correlated with HDL- cholesterol
blood levels. This association however did not reach a
statistical significance (p = 0.056). There was no cor-
relation between UII and total cholesterol, LDL -
cholesterol and triglycerides levels (p = 0.948, p = 0.882
and p = 0.230 respectively).








Urea (mg/dl) 78 [49, 128]a 162 [135, 203]b 47.5 [37, 66]c <0.001
Creatinine (mg/dl) 1.7 [1.3, 2.3]a 7.4 [6.8, 9]b 1 [0.8, 1.2]c <0.001
Cystatin (mg/L) 1.85 [1.53, 3.25]a 6.54 [6.15, 6.96]b 1.42 [1.04, 1.67]c <0.001
Uric acid (mg/dl) 7.1 (1.85)a 7.0 (1.36)ab 5.88 (1.34)b 0.010
Sodium (mEq/L) 138 [137, 140] 137 [136, 139] 138 [137, 139] 0.426
Potassium (mEq/L) 4.6 [4.4, 5]ab 5 [4.7, 5.5]a 4.4 [4.2, 4.7]b 0.011
Chloride (mEq/L) 103 [101, 104]ac 97.5 [91.5, 99]b 104 [102, 108]c <0.001
Ca (mg/dl) 9.9 [9.7 , 10.2] 10.1 [9.7, 10.3] 10 [9.7, 10.3] 0.860
P (mg/dl) 4.4 [4.1, 4.9] 5 [4.5, 6.9] 4.1 [4.0, 4.3] 0.008
ALT (U/L) 22 [18, 28] 18 [17, 23] 17.5 [17, 19] 0.174
AST (U/L) 14 [12, 21] 16 [12, 24] 13.5 [11, 16] 0.274
γGT (U/L) 12 [10, 14] 12 [8, 48] 12 [10, 16] 0.951
Total Protein (g/dl) 7.39 (0.54)a 6.78 (0.47)b 6.72 (0.62)b <0.001
Albumin (g/dl) 4.59 (0.23)a 4.28 (0.33)b 4.48 (0.30)ab 0.010
pH 7.35 (0.03) 7.37 (0.04) 7.35 (0.03) 0.134
HCO3 (mEq/L) 22.0 (2.57) 24.4 (4.10) 22.19 (3.67) 0.147
Acidosis (Yes %) 39.1 15.4 41.2 0.263
Hct (%) 37.4 (4.14)a 32.7 (4.62)b 35.6 (5.14)ab 0.018
Hb (g/dL) 12.5 (1.53)a 10.7 (1.40)b 11.7 (1.66)ab 0.008
Anemia (Yes %) 34.8 76.9 55.6 0.051
CKD chronic Kidney Disease, RTR Renal Transplant Recipients, HD Hemodialysis. *Results are presented as mean (SD) or as median [IQR] according to data
distribution. Superscript letters a, b, c denote values of different statistical significance
Fig. 2 Box plot of UII levels by group. CKD: chronic Kidney Disease,
HD: Hemodialysis, RTR: Renal Transplant Recipients
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Discussion
The current study indicates that children and adolescents
with CKD, especially patients who underwent renal trans-
plantation and patients with no dialysed CKD, have sig-
nificantly higher plasma urotensin II (UII) levels
compared to healthy controls. Moreover, plasma UII con-
centration was significantly increased at the end of the
HD session and was similar to that of RTR and CKD pa-
tients and higher than healthy controls. The only factor
that seems to affect significantly plasma UII levels is the
presence of metabolic acidosis. The effect of left ventricu-
lar mass (LVM) in UII levels was of marginal significance.
Plasma UII levels have hardly been studied in children
and adolescents with renal diseases. A study in children
with minimal change nephrotic syndrome revealed that
plasma UII levels were lower and urinary UII levels were
higher in relapse than those in remission. This difference
was attributed to proteinuria. Moreover, patients, in re-
lapse and in remission, had lower plasma and urine UII
concentrations compared to healthy controls. Plasma
UII had a strong correlation with plasma albumin, only
in remission [22]. More dense UII immunoreactivity in
renal biopsy specimens of children with membranoproli-
ferative glomerulonephritis compared to healthy kidneys
has been found and a possible autocrine/paracrine func-
tion of UII in kidneys has been considered [23].
To our knowledge there are no studies of plasma UII
in children and adolescents with chronic kidney disease
or in renal transplant recipients.
A few studies have evaluated plasma UII levels in
adults with CKD or ESKD on HD and only one in RTR
adults. The contradictory results of these studies may be
mainly due to different methodology such as the hetero-
geneous populations of patients and controls, and the
assays used for the determination of UII levels.
The first study of plasma UII-like immunoreactivity in
adults with CKD was published fourteen years ago [9].
Plasma UII levels were higher in patients with CKD, es-
pecially those with ESKD on HD, compared to controls,
although UII levels did not correlate with serum creatin-
ine. Contrary to our study no significant change of UII
levels at the end of the HD session was noted. Totsune
et al assumed that increased UII may be the result of the
decreased excretion from the kidney or of increased pro-
duction. In addition, it was found that mRNA encoding
UII precursor and its receptor was expressed not only in
renal but also in many other tissues such as in the heart
[9]. Three years later the same authors reported 1.6
times higher plasma UII levels in diabetic patients with
severe CKD compared to patients with mild to moderate
CKD. Furthermore, patients with more severe disease
had 1.8 times higher urinary UII excretion than healthy
controls [10].










Urotensin II 3.53 [2.49, 4.46]a 2.42 [1.60, 2.79]ab 4.16 [2.53, 6.96]a 1.28 [1.08, 1.63]b <0.001
Log - Urotensin II 1.22 (0.71)acd 0.71 (0.53)bd 1.33 (0.95)c 0.36 (0.54)b <0.001
Tests employed are one way ANOVA, and Kruskal – Wallis test, respectively. Different letters denote statistical significant difference between groups (p < 0.05)
CKD Chronic Kidney Disease, HD Hemodialysis, RTR Renal Transplant Recipients
*Results are presented as mean (SD) or as median [IQR] according to data distribution
Table 4 Linear regression analysis of log-UT II adjusted for pH,
HCO3 and metabolic acidosis by group*
Factor Coefficient S.D P-value 95% C.I.
L.L U.L.
HD** -0.39 0.257 0.135 -0.91 0.12
RTR*** -0.004 0.233 0.985 -0.47 0.46
pH -7.03 3.061 0.023 -13.18 -0.88
HD** -0.31 0.279 0.273 -0.87 0.25
RTR*** 0.06 0.235 0.793 -0.41 0.53
HCO3 -0.07 0.032 0.040 -0.13 -0.003
HD** -0.37 0.253 0.144 -0.88 0.13
RTR*** 0.04 0.228 0.857 -0.41 0.50
Acidosis 0.57 0.170 0.010 0.14 0.99
*Reference group: CKD: Chronic Kidney Disease, **HD: Hemodialysis
***RTR: Renal Transplant Recipients
Table 5 Linear regression analysis of log-UT II adjusted for LVMI,
LVM and Heart Rate by group*
Factor Coefficient S.D P-value 95% C.I.
L.L U.L.
HD** -0.53 0.28 0.065 -1.09 0.33
RTR*** 0.17 0.25 0.489 -0.32 0.67
LVMI 0.00025 0.0026 0.921 -0.0049 0.0054
HD** -0.59 0.29 0.047 -1.18 -0.009
RTR*** 0.15 0.25 0.536 -0.34 0.65
LVM 0.0039 0.006 0.554 -0.009 0.017
HD** -0.46 0.27 0.093 -1.02 0.80
RTR*** 0.12 0.25 0.642 -0.38 0.61
HR -0.004 0.005 0.448 -0.015 0.006
LVMI Left Ventricular Mass Index, LVM Left Ventricular Mass, HR Heart Rate
*Reference group: CKD: Chronic Kidney Disease, **HD: Hemodialysis,
***RTR: Renal Transplant Recipients
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Twofold higher plasma UII levels were found in
patients with ESKD on hemodialysis (HD) compared to
healthy controls in another study. Moreover, UII was an
independent, inverse predictor of cardiovascular (CV)
events in those patients [17]. An inverse correlation has
also been observed between UII and some biomarkers of
atherosclerosis and endothelial activation in ESKD
patients undergoing HD. Furthermore, UII levels were
lower in patients who received antihypertensive medica-
tion [28]. However, it remains unclear whether the
hypertensive treatment or the hypertension influences
UII levels [29]. A negative association between UII and
CV stress hormones such as norepinephrine and brain
natriuretic peptide (BNP) in patients on HD has also
been considered, suggesting that higher UII concentra-
tion may be vasculoprotective [30]. The results of all the
above mentioned studies contradict previous ones in
which a positive correlation between increased UII and
cardiovascular diseases was reported [31, 32]. A direct
association of circulating UII with left ventricular sys-
tolic function and an inverse association with left atrial
volume were considered, by Zoccali et al. [33], in the
same patients recorded by Mallamaci F et al. [28]. These
data further support the hypothesis that high UII is car-
dioprotective in adult ESKD patients.
Similarly, UII concentration was inversely correlated
with the history of CV events as well with a lower risk
of death from CV or other causes in adults with earlier
stages of CKD [18].
Higher urinary UII-like immunoreactivity was found
in hypertensive adults with normal renal function
compared to controls. Furthermore, the hypertensive
patients with renal disease had higher urinary UII-like
immunoreactivity than normotensive patients with renal
disease [34]. Greater plasma UII concentration in hyper-
tensive compared to normotensive subjects has also
been considered [6]. Increased expression of UII-related
peptide and its receptor’s mRNAs in the kidneys of rats
with hypertension and chronic kidney failure has been
established [35].
Contrary to other studies, Mosenkis A et al., showed
lower UII concentrations mainly in CKD as well in
ESRD patients than controls. UII was negatively corre-
lated with serum creatinine and the stage of CKD and
positively with creatinine clearance. However the au-
thors noticed an increase in UII levels at the end of the
HD session [36]. Furthermore, in a recent study, predia-
lysis of UII levels were lower in overhydrated compared
to normohydrated ESKD patients [37]. Taking into con-
sideration previous reports on the relationship between
low UII concentration and the risk of cardiovascular
events in patients with CKD, the authors assume that
low levels may be a therapeutic target in overhydrated
CKD patients [37].
It is speculated, that the removal of fluids from our
patients by HD and the resulting hemoconcentration
may have a role in the increase of HDII levels after the
completion of HD [36, 37]. Moreover, UII is a middle
size molecule (molecular mass = 1388.6 g/mol) and is
only partially removed using the convential HD [36, 38].
In addition, the removal of fluids which leads to a reduc-
tion in blood pressure and to the improvement of many
biochemical parameters, may have as a result an increased
production of UII by the heart or other tissues [9, 36].
According to our results, there was no significant correl-
ation found between UII and blood pressure measure-
ments. These results agree with Mosenkis et al., who
considered that this might be due to antihypertensive
treatment [36].
Another recent study evaluated, for the first time,
plasma UII levels in adults with RTR. The authors found
significantly higher UII levels in RTR compared to CKD
and to healthy controls.. This could not be explained
solely by the transplanted kidney, because UII levels
were higher than healthy controls and It was assumed
that this could be immunosuppressive drug-related.
However, the immunosuppressive drug doses and the
duration of transplantation did not correlate with UII
levels [39]. In our study, RTR children had significantly
higher UII levels compared to healthy controls and
higher but without statistical significance UII levels than
CKD patients. There was also no correlation between
UII and the duration of renal transplantation. We can-
not support that immunosuppressive treatment was re-
sponsible for higher UII concentration of RRT patients,
because of the small number of participants.
Another finding of our study was the correlation
between UII and metabolic acidosis. The increase of pH
was associated with a decrease of UII which was inde-
pendent from all other parameters. There are no studies
evaluating the correlation between these two markers. A
study in human smooth muscle cells showed that UII
affected intracellular pH inducing acidosis [40]. The high
percentage of RTR patients with metabolic acidosis
might be immunosuppressive drug-related [41]. A
correlation of metabolic acidosis and protein catabolism
is documented in a number of studies [42–44]. Protein
catabolism might trigger the increase of UII.
UII levels did not differ significantly between males
and females of this study and did not correlate with age in
patients and controls. This is in accordance with most of
the above mentioned studies [9, 36, 45]. On the contrary,
a significant correlation between age and UII has been re-
ported [6] and Hurshitoglu et al [39] observed that males
tended to have higher levels of UII than females.
The main limitations of this study is the small number
of participants per group and the absence of repeated
measurements of UII after a certain period of time.
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Conclusions
Children and adolescents with chronic kidney disease, as
well as renal transplant recipients, have significantly
higher urotensin II levels than healthy controls. This
could not be attributed solely to renal failure, since renal
transplanted subjects had higher levels than healthy
controls, non dialyzed CKD and HD patients. The effect
of immunosuppressive therapy may play a role for these
findings. The increase of urotensin II concentration at
the end of the HD session might be the result of the cor-
rection of overhydration, the changes in biochemical
and clinical parameters as well as the use of conven-
tional hemodialysis.
Larger prospective studies of children with renal dis-
ease are required in order to establish plasma urotensin
II levels and clarify its importance regarding the evalu-
ation, follow up and management of these patients.
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